0000950170-24-072199.txt : 20240611 0000950170-24-072199.hdr.sgml : 20240611 20240611203418 ACCESSION NUMBER: 0000950170-24-072199 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240611 FILED AS OF DATE: 20240611 DATE AS OF CHANGE: 20240611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Squarer Ron CENTRAL INDEX KEY: 0001454001 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 241037298 MAIL ADDRESS: STREET 1: C/O ADC THERAPEUTICS SA STREET 2: BIOPOLE, ROUTE DE LA CORNICHE 3B CITY: EPALINGES STATE: V8 ZIP: 1066 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 ownership.xml 4 X0508 4 2024-06-11 true 0001654151 Deciphera Pharmaceuticals, Inc. NA 0001454001 Squarer Ron C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM MA 02451 true false false false false Stock Option (Right to Buy) 8.27 2024-06-11 4 D false 9570 D Common Stock 9570 0 D Stock Option (Right to Buy) 13.98 2024-06-11 4 D false 18500 D Common Stock 18500 0 D Stock Option (Right to Buy) 21.27 2024-06-11 4 D false 3269 D Common Stock 3269 0 D Stock Option (Right to Buy) 14.91 2024-06-11 4 D false 30000 D Common Stock 30000 0 D Stock Option (Right to Buy) 14.46 2024-06-11 4 D false 4727 D Common Stock 4727 0 D This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. /s/ Jeffrey M. Held, Attorney-in-Fact 2024-06-11